AstraZeneca-Oxford COVID-19 vaccine side effects have raised worries, but the pharmaceutical behemoth has acknowledged that the vaccination can, in rare instances, cause blood clots and low platelet counts. On Tuesday, the company reaffirmed its commitment to patient safety. The Serum Institute of India manufactured the vaccine, which was widely given throughout the nation and sold as Covishield there.
AstraZeneca has previously acknowledged side effects related to the Covid vaccine; however, in a UK court case involving a class action lawsuit against the pharmaceutical company for 100 million pounds, the company acknowledged that the vaccine can, in extremely rare circumstances, cause thrombosis thrombocytopenia syndrome (TTS).
“Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines,” AstraZeneca said in a statement.
Global regulatory bodies are still of the opinion that vaccinations have far greater advantages than disadvantages, including extremely rare adverse effects.
According to the World Health Organisation (WHO), the vaccine is “safe and effective for all individuals aged 18 and above,” and the unfavourable outcome that sparked the lawsuit is “very rare.”
The Covishield COVID-19 vaccine was created by the Serum Institute of India with a viral vector platform as opposed to mRNA technology. The COVID-19 spike protein is delivered into human cells by means of the chimpanzee adenovirus, ChAdOx1, which has been modified for this vaccine. Although it is unable to successfully infect its targets, this cold virus successfully “teaches” the immune system how to fight against related viruses.
